Cargando…
Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study
PURPOSE: For patients who have chondrosarcoma in the unresectable setting, antiangiogenic agents are reportedly effective. This multicenter, retrospective study investigated the antitumor activity of apatinib in patients with unresectable chondrosarcoma to gain insight into the biological behavior o...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237692/ https://www.ncbi.nlm.nih.gov/pubmed/32547189 http://dx.doi.org/10.2147/CMAR.S253201 |
_version_ | 1783536381123887104 |
---|---|
author | Xie, Lu Xu, Jie Sun, Xin Liu, Kuisheng Li, Xiaowei He, Fangzhou Liu, Xinyu Gu, Jin Lv, Zhe Yang, Rongli Tang, Xiaodong Yan, Taiqiang Li, Dasen Yang, Yi Dong, Sen Sun, Kunkun Shen, Danhua Guo, Wei |
author_facet | Xie, Lu Xu, Jie Sun, Xin Liu, Kuisheng Li, Xiaowei He, Fangzhou Liu, Xinyu Gu, Jin Lv, Zhe Yang, Rongli Tang, Xiaodong Yan, Taiqiang Li, Dasen Yang, Yi Dong, Sen Sun, Kunkun Shen, Danhua Guo, Wei |
author_sort | Xie, Lu |
collection | PubMed |
description | PURPOSE: For patients who have chondrosarcoma in the unresectable setting, antiangiogenic agents are reportedly effective. This multicenter, retrospective study investigated the antitumor activity of apatinib in patients with unresectable chondrosarcoma to gain insight into the biological behavior of this disease. METHODS: All of the patients with unresectable chondrosarcoma who were diagnosed between October 1, 2009, and November 1, 2019, in two sarcoma centers affiliated with Peking University were evaluated. Relevant information was collected from the medical records at both centers, from which patients receiving apatinib for systemic therapy were selected for analysis. RESULTS: In total, efficacy analysis was conducted in 33 patients with a median follow-up time of 22.1 (Q1, Q3, 14.6, 23.0) months. There were 20/33 (60.0%) conventional chondrosarcomas (grades 2–3), 5/33 (15.2%) dedifferentiated chondrosarcomas, 4/33 (12.1%) mesenchymal chondrosarcomas, 3/33 (9.1%) extraskeletal myxoid chondrosarcoma, and 1/33 (3.1%) clear-cell chondrosarcomas with 87.9% in metastatic and 12.1% in locally advanced states. The objective response rate was 6/33 (18.2%). The median progression-free survival (PFS) was 12.4 months (Q1, Q3, 7.0, 21.2), while the median overall survival has not yet been reached. Rare variants of chondrosarcoma tended to have a longer PFS than conventional chondrosarcoma (P=0.06). Based on clinicopathological factors Cox and univariate analysis, only extraskeletal myxoid chondrosarcoma and baseline target lesions <60 mm benefited from the drug apatinib (P=0.14 and P=0.00), respectively. Grade 3 or higher adverse events were frequent in 11/33 (39.3%) of patients who discontinued apatinib due to deterioration of their general condition. CONCLUSION: Apatinib had clinically meaningful activity in patients with inoperable high-grade chondrosarcoma. However, special caution should be made in managing toxicity due to the indolent behavior and slow growth pattern after using this drug. Patients with a smaller tumor size and extraskeletal myxoid chondrosarcoma subtype might benefit from this therapy more. CLINICAL TRIAL REGISTRATION: Registered February 7, 2020, with clinicaltrials.gov: NCT04260113. |
format | Online Article Text |
id | pubmed-7237692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-72376922020-06-15 Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study Xie, Lu Xu, Jie Sun, Xin Liu, Kuisheng Li, Xiaowei He, Fangzhou Liu, Xinyu Gu, Jin Lv, Zhe Yang, Rongli Tang, Xiaodong Yan, Taiqiang Li, Dasen Yang, Yi Dong, Sen Sun, Kunkun Shen, Danhua Guo, Wei Cancer Manag Res Original Research PURPOSE: For patients who have chondrosarcoma in the unresectable setting, antiangiogenic agents are reportedly effective. This multicenter, retrospective study investigated the antitumor activity of apatinib in patients with unresectable chondrosarcoma to gain insight into the biological behavior of this disease. METHODS: All of the patients with unresectable chondrosarcoma who were diagnosed between October 1, 2009, and November 1, 2019, in two sarcoma centers affiliated with Peking University were evaluated. Relevant information was collected from the medical records at both centers, from which patients receiving apatinib for systemic therapy were selected for analysis. RESULTS: In total, efficacy analysis was conducted in 33 patients with a median follow-up time of 22.1 (Q1, Q3, 14.6, 23.0) months. There were 20/33 (60.0%) conventional chondrosarcomas (grades 2–3), 5/33 (15.2%) dedifferentiated chondrosarcomas, 4/33 (12.1%) mesenchymal chondrosarcomas, 3/33 (9.1%) extraskeletal myxoid chondrosarcoma, and 1/33 (3.1%) clear-cell chondrosarcomas with 87.9% in metastatic and 12.1% in locally advanced states. The objective response rate was 6/33 (18.2%). The median progression-free survival (PFS) was 12.4 months (Q1, Q3, 7.0, 21.2), while the median overall survival has not yet been reached. Rare variants of chondrosarcoma tended to have a longer PFS than conventional chondrosarcoma (P=0.06). Based on clinicopathological factors Cox and univariate analysis, only extraskeletal myxoid chondrosarcoma and baseline target lesions <60 mm benefited from the drug apatinib (P=0.14 and P=0.00), respectively. Grade 3 or higher adverse events were frequent in 11/33 (39.3%) of patients who discontinued apatinib due to deterioration of their general condition. CONCLUSION: Apatinib had clinically meaningful activity in patients with inoperable high-grade chondrosarcoma. However, special caution should be made in managing toxicity due to the indolent behavior and slow growth pattern after using this drug. Patients with a smaller tumor size and extraskeletal myxoid chondrosarcoma subtype might benefit from this therapy more. CLINICAL TRIAL REGISTRATION: Registered February 7, 2020, with clinicaltrials.gov: NCT04260113. Dove 2020-05-15 /pmc/articles/PMC7237692/ /pubmed/32547189 http://dx.doi.org/10.2147/CMAR.S253201 Text en © 2020 Xie et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Xie, Lu Xu, Jie Sun, Xin Liu, Kuisheng Li, Xiaowei He, Fangzhou Liu, Xinyu Gu, Jin Lv, Zhe Yang, Rongli Tang, Xiaodong Yan, Taiqiang Li, Dasen Yang, Yi Dong, Sen Sun, Kunkun Shen, Danhua Guo, Wei Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study |
title | Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study |
title_full | Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study |
title_fullStr | Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study |
title_full_unstemmed | Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study |
title_short | Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study |
title_sort | apatinib for treatment of inoperable metastatic or locally advanced chondrosarcoma: what we can learn about the biological behavior of chondrosarcoma from a two-center study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237692/ https://www.ncbi.nlm.nih.gov/pubmed/32547189 http://dx.doi.org/10.2147/CMAR.S253201 |
work_keys_str_mv | AT xielu apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT xujie apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT sunxin apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT liukuisheng apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT lixiaowei apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT hefangzhou apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT liuxinyu apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT gujin apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT lvzhe apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT yangrongli apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT tangxiaodong apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT yantaiqiang apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT lidasen apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT yangyi apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT dongsen apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT sunkunkun apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT shendanhua apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy AT guowei apatinibfortreatmentofinoperablemetastaticorlocallyadvancedchondrosarcomawhatwecanlearnaboutthebiologicalbehaviorofchondrosarcomafromatwocenterstudy |